51. A retrospective multicentric study of ewing sarcoma family of tumors in patients older than 50:management and outcome
- Author
-
Loic Chaigneau, Dominique Levy, Philippe A. Cassier, Pauline Rochefort, Pierre Meeus, François Bertucci, Emmanuelle Bompas, Valérie Laurence, Antoine Italiano, Thomas Ryckewaert, Audrey Lardy-Cleaud, Nicolas Penel, Sarah Dumont, Christine Chevreau, Olivier Mir, Jean-Yves Blay, Dominique Ranchère, CHU Lille, Université de Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Centre Léon Bérard [Lyon], Institut Curie [Paris], Institut Gustave Roussy [IGR], Institut Paoli-Calmettes, CRLCC René Gauducheau, Institut Bergonié [Bordeaux], UNICANCER, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut Gustave Roussy (IGR), Institut Claudius Regaud, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Université de Lille-UNICANCER
- Subjects
Male ,0301 basic medicine ,Lung Neoplasms ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,lcsh:Medicine ,Disease ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,lcsh:Science ,Aged, 80 and over ,EFTS ,Multidisciplinary ,Soft tissue ,Middle Aged ,Combined Modality Therapy ,Primary tumor ,3. Good health ,Survival Rate ,Treatment Outcome ,Surgical Procedures, Operative ,030220 oncology & carcinogenesis ,Female ,Sarcoma ,medicine.medical_specialty ,Bone Neoplasms ,Sarcoma, Ewing ,macromolecular substances ,Article ,03 medical and health sciences ,Internal medicine ,otorhinolaryngologic diseases ,Humans ,Aged ,Retrospective Studies ,Chemotherapy ,Radiotherapy ,business.industry ,lcsh:R ,medicine.disease ,Clinical trial ,carbohydrates (lipids) ,stomatognathic diseases ,030104 developmental biology ,Localized disease ,bacteria ,lcsh:Q ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Ewing’s sarcoma family of tumors (EFTs) is a group of rare and aggressive tumors. Data on EFTs in patients (pts) ≥ 50 years are limited and these pts are often not eligible for clinical trials. Some, but not all, studies have reported inferior outcome for older pts with EFTs. We conducted an IRB-approved retrospective analysis among centers of the French Sarcoma Group on pts diagnosed with EFTs at age ≥50 between 2000 and 2012. Clinical features, treatment modality and outcomes were analyzed. Seventy-seven pts were identified, including 36 females (46.8%) and the median age at diagnosis was 56 years (range: 50–86). The primary tumor was located in soft tissue in 59 pts (76.6%). Fifty-six pts (72.7%) had localized disease, among them 49 (87.5%) received chemotherapy in addition to local therapy. Their estimated 3-yr OS and event-free survival (EFS) rates were respectively 73.3% and 62.2%. Recurrence occurred in 43 pts. The estimated 3-yr OS rate was 37% in pts with metastatic disease at presentation. EFTs in pts ≥50 years are more likely to originate from soft tissue and their outcomes appear to be worse than that of younger pts treated with modern protocols.
- Published
- 2017